Compare ARK Genomic Revolution ETF (ARKG) vs Icl Group Ltd (ICL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Icl Group Ltd — how do they compare? ARK Genomic Revolution ETF trades at $40.83, while Icl Group Ltd trades at $4.87 (market cap $6.30B). The key difference: Icl Group Ltd pays a 3.93% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Icl Group Ltd nearer its low. Which is the better fit depends on your goals.
| ARKG | ICL | |
|---|---|---|
Sector | Sector/Thematic | Basic Materials |
52-Week High | $43.57 | $7.07 |
52-Week Low | $23.09 | $4.80 |
Market Cap | — | $6.30B |
Enterprise Value | — | $8.87B |
Dividend Yield | — | 3.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
ICL trades at $4.85, unchanged on the day, with a bearish technical signal from moving averages. The company reported Q1 2026 earnings of $0.11 per share, beating expectations, and recently completed an $800 million senior notes offering. Revenue for 2025 was $7.15 billion, with a net income margin of 3.52% and a P/E ratio of 23.1. Analyst consensus is entirely Hold, with no Buy or Sell ratings among the four covering firms.
ICL faces headwinds from declining profit margins and elevated raw material costs, but operational improvements and raised 2026 EBITDA guidance offer some upside. Key risks include geopolitical tensions and foreign exchange volatility. The stock's current valuation appears fair, with limited near-term catalysts given the neutral analyst sentiment and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
